#1 Clinical Trials Search in Europe

Tobramycin

Tobramycin is an antibiotic commonly used to treat lung infections in patients with cystic fibrosis and bronchiectasis. This article examines various clinical trials investigating different formulations and delivery methods of tobramycin, including nebulized solutions, dry powder inhalers, and novel devices. The studies aim to improve treatment efficacy, patient convenience, and quality of life for those requiring long-term antibiotic therapy.

Table of Contents

What is Tobramycin?

Tobramycin is an antibiotic medication primarily used to treat certain bacterial infections, particularly those caused by Pseudomonas aeruginosa. This bacterium is known to cause serious lung infections in people with certain chronic respiratory conditions[1]. Tobramycin belongs to a class of antibiotics called aminoglycosides, which work by killing bacteria or preventing their growth[2].

Tobramycin is available under various brand names, including:

  • TOBI
  • Bramitob
  • Bethkis
  • Tobrineb
  • Actitob
  • Vantobra
  • Nebcinal

What Conditions Does Tobramycin Treat?

Tobramycin is primarily used to treat the following conditions:

  1. Cystic Fibrosis (CF): This is a genetic disorder that affects the lungs and other organs. Tobramycin is commonly used to treat chronic lung infections caused by Pseudomonas aeruginosa in CF patients[1].
  2. Non-Cystic Fibrosis Bronchiectasis: This is a condition where the airways of the lungs become abnormally widened, leading to a build-up of excess mucus. Tobramycin can be used to treat Pseudomonas aeruginosa infections in these patients[3].
  3. Other Pseudomonas aeruginosa Infections: Tobramycin may be used to treat various other infections caused by this bacterium, particularly in the lungs[4].

How is Tobramycin Administered?

Tobramycin is typically administered through inhalation, allowing it to reach the lungs directly. There are several ways to inhale tobramycin:

  1. Nebulizer Solution: This is a liquid form of tobramycin that is turned into a mist by a machine called a nebulizer. The mist is then inhaled through a mask or mouthpiece[1].
  2. Dry Powder Inhaler: This is a device that delivers tobramycin as a dry powder. Examples include the TOBI Podhaler and the Cyclops device[5][3].
  3. Soft Mist Inhaler: This is a newer type of device that creates a fine mist of medication without using propellants[4].

Effectiveness of Tobramycin

Tobramycin has been shown to be effective in treating Pseudomonas aeruginosa infections in patients with cystic fibrosis and non-CF bronchiectasis. It can help:

  • Improve lung function[1]
  • Reduce the density of Pseudomonas aeruginosa in the lungs[6]
  • Decrease the frequency of hospitalizations[7]
  • Improve quality of life[7]

Dosage and Administration

The dosage and administration of tobramycin can vary depending on the specific product and the patient’s condition. However, some common regimens include:

  • 300 mg twice daily for 28 days, followed by 28 days off treatment[1]
  • 170 mg twice daily[8]
  • 112 mg (4 x 28 mg capsules) twice daily for dry powder inhalers[9]

It’s important to note that the dosage should always be determined by a healthcare professional based on individual patient factors.

Potential Side Effects

While tobramycin is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Cough
  • Wheezing
  • Shortness of breath
  • Throat irritation
  • Changes in voice

In rare cases, tobramycin may cause more serious side effects such as hearing loss or kidney problems. It’s important to report any unusual symptoms to your healthcare provider[3][7].

Ongoing Research

Research on tobramycin is ongoing, with studies focusing on:

  • New delivery methods to improve efficiency and ease of use[5][9]
  • Different dosing regimens to optimize treatment[6]
  • Use in non-CF bronchiectasis patients[7]
  • Comparison of different tobramycin products[8]

These studies aim to improve the effectiveness of tobramycin treatment and expand its use to benefit more patients with chronic lung infections.

Aspect Details
Drug Formulations Nebulized solutions (e.g., TOBI®, Bramitob®), Dry powder inhalers (e.g., TOBI® Podhaler™), Novel devices (e.g., Cyclops®, TobrAir® 6.0)
Target Conditions Cystic Fibrosis, Non-CF Bronchiectasis
Main Objectives Evaluate pharmacokinetics, bioequivalence, efficacy, safety, and tolerability of different tobramycin formulations
Key Outcome Measures Lung function (FEV1), Bacterial load in sputum, Pharmacokinetic parameters (AUC, Cmax, Tmax), Adverse events, Quality of life
Potential Advantages of New Formulations Faster administration, Higher lung deposition, Improved patient convenience, Reduced risk of device contamination
Study Designs Randomized controlled trials, Crossover studies, Open-label studies, Dose-escalation studies
Patient Populations Adults and children with CF, Adults with non-CF bronchiectasis, Healthy volunteers (for pharmacokinetic studies)

FAQ

  • What is tobramycin used for in these clinical trials? Tobramycin is primarily used to treat chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis.
  • What are the different ways tobramycin is administered in these trials? The trials explore various administration methods, including nebulized solutions, dry powder inhalers (DPIs), and novel devices like the Cyclops® and TobrAir® 6.0.
  • Why are researchers looking at new ways to deliver tobramycin? Researchers are exploring new delivery methods to improve lung deposition, reduce treatment time, enhance patient convenience, and potentially increase treatment efficacy compared to traditional nebulizers.
  • What are some of the main outcomes measured in these tobramycin trials? The trials measure outcomes such as pharmacokinetics (how the drug moves through the body), lung function changes, bacterial load in sputum, drug tolerability, and quality of life improvements.
  • Are there any potential advantages of dry powder tobramycin over nebulized solutions? Dry powder inhalers may offer advantages such as faster administration times, higher lung deposition, and reduced risk of device contamination compared to nebulized solutions.

Ongoing Clinical Trials on Tobramycin

  • Comparing the effectiveness of nepafenac and dexamethasone sodium phosphate for treating eye inflammation after cataract surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Shortened Antibiotic Treatment for Gram-negative Bacteremia in Hospitalized Adults Using Pivmecillinam Hydrochloride and Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark

  • Study on Preventing Infections After Esophageal Cancer Surgery Using Colistin Sulfate, Tobramycin, and Amphotericin B in Patients with Resectable Esophageal Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium The Netherlands

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on Inhaled Tobramycin and Colistimethate Sodium for Adults with Chronic Bronchial Infection in Bronchiectasis

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Cystic Fibrosis (CF): A genetic disorder that affects the lungs, pancreas, and other organs, causing thick, sticky mucus to build up and leading to frequent lung infections.
  • Bronchiectasis: A condition where the airways of the lungs become abnormally widened, leading to a build-up of excess mucus that makes the lungs more vulnerable to infection.
  • Pseudomonas aeruginosa: A type of bacteria that commonly infects the lungs of people with cystic fibrosis and can be difficult to treat due to its resistance to many antibiotics.
  • Nebulizer: A device that turns liquid medication into a fine mist that can be inhaled directly into the lungs.
  • Dry Powder Inhaler (DPI): A device that delivers medication to the lungs in the form of a dry powder, which is inhaled by the patient.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • Bioequivalence: The property of two drug products having the same biological effect in the body.
  • MIC (Minimum Inhibitory Concentration): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • Sputum: Mucus and other matter brought up from the lungs by coughing.

References

  1. https://clinicaltrials.gov/study/NCT00885365
  2. https://clinicaltrials.gov/study/NCT01288170
  3. https://clinicaltrials.gov/study/NCT02035488
  4. https://clinicaltrials.gov/study/NCT00634192
  5. https://clinicaltrials.gov/study/NCT03485456
  6. https://clinicaltrials.gov/study/NCT01608555
  7. https://clinicaltrials.gov/study/NCT02102152
  8. https://clinicaltrials.gov/study/NCT01953367
  9. https://clinicaltrials.gov/study/NCT02207426